Eli Lilly: limited earnings growth in Q3

(CercleFinance.com) - Eli Lilly has reported a 3% increase in Q3 adjusted net income to 1.
41 billion dollars, or 1.54 dollar per share, with EPS significantly lower than expected, while revenues rose by 5% to 5.74 billion dollars.

The pharmaceutical company said that its key growth products that have been launched since 2014, such as Trulicity, Verzenio and Cyramza, contributed nine percentage points to revenue growth and accounted for approximately 52% of its total revenues.

For FY 2020, the Indianapolis-based group confirms that it expects adjusted EPS of 7.20-7.40 dollars, with revenues of 23.7-24.2 billion dollars. In addition, it estimates its R&D spending on Covid-19 to be around 400 million dollars this year.


Copyright (c) 2020 CercleFinance.com. All rights reserved.